Researchers at Robert W. Baird Kept their “Buy” rating for Digital Realty (DLR). The Price Target Given is $124.0; 2 Analysts Covering Silence Therapeutics plc (LON:SLN)

January 16, 2018 - By Marguerite Chambers

Among 2 analysts covering Silence Therapeutics PLC (LON:SLN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Silence Therapeutics PLC had 8 analyst reports since September 29, 2015 according to SRatingsIntel. Canaccord Genuity maintained it with “Buy” rating and GBX 249 target in Monday, January 9 report. As per Thursday, August 11, the company rating was maintained by Canaccord Genuity. The firm earned “Buy” rating on Monday, January 8 by Peel Hunt. The stock of Silence Therapeutics plc (LON:SLN) has “Buy” rating given on Thursday, December 28 by Peel Hunt. The company was maintained on Tuesday, December 20 by Canaccord Genuity. Canaccord Genuity maintained the stock with “Buy” rating in Tuesday, September 27 report. The stock of Silence Therapeutics plc (LON:SLN) earned “Buy” rating by Canaccord Genuity on Tuesday, September 29. See Silence Therapeutics plc (LON:SLN) latest ratings:

08/01/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 276.00 New Target: GBX 276.00 Maintain
28/12/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 275.00 New Target: GBX 275.00 Maintain
14/12/2017 Broker: Peel Hunt Rating: Buy New Target: GBX 276.00 Initiates Starts

Among 20 analysts covering Digital Realty Trust (NYSE:DLR), 10 have Buy rating, 1 Sell and 9 Hold. Therefore 50% are positive. Digital Realty Trust has $140.0 highest and $67 lowest target. $120.06’s average target is 13.50% above currents $105.78 stock price. Digital Realty Trust had 74 analyst reports since July 31, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Monday, November 2 by RBC Capital Markets. The firm earned “Outperform” rating on Friday, May 13 by RBC Capital Markets. The company was upgraded on Thursday, December 8 by Citigroup. The rating was maintained by KeyBanc Capital Markets on Monday, December 14 with “Overweight”. The firm has “Hold” rating by Jefferies given on Friday, July 14. The stock of Digital Realty Trust, Inc. (NYSE:DLR) earned “Buy” rating by Cowen & Co on Friday, August 25. The firm has “Neutral” rating given on Tuesday, December 22 by JP Morgan. The rating was downgraded by Jefferies to “Hold” on Tuesday, July 19. The stock of Digital Realty Trust, Inc. (NYSE:DLR) earned “Overweight” rating by Barclays Capital on Monday, October 19. SunTrust maintained it with “Buy” rating and $140.0 target in Wednesday, December 6 report.

Investors sentiment increased to 2.06 in Q3 2017. Its up 1.03, from 1.03 in 2017Q2. It increased, as 44 investors sold Digital Realty Trust, Inc. shares while 119 reduced holdings. 95 funds opened positions while 241 raised stakes. 198.28 million shares or 22.83% more from 161.43 million shares in 2017Q2 were reported. Barclays Public Ltd Company holds 0.04% or 292,404 shares. Kayne Anderson Advisors L P invested in 0.04% or 23,900 shares. Fincl Bank Of America Corporation De has invested 0.2% of its portfolio in Digital Realty Trust, Inc. (NYSE:DLR). Hartford Investment Mgmt has invested 0.1% of its portfolio in Digital Realty Trust, Inc. (NYSE:DLR). New York-based Canandaigua Retail Bank And Company has invested 0.3% in Digital Realty Trust, Inc. (NYSE:DLR). Sun Life Finance stated it has 0.02% in Digital Realty Trust, Inc. (NYSE:DLR). Ipswich Investment Mngmt accumulated 0.09% or 1,765 shares. Caldwell And Orkin Inc stated it has 2.64% in Digital Realty Trust, Inc. (NYSE:DLR). Illinois-based Northern Trust has invested 0.11% in Digital Realty Trust, Inc. (NYSE:DLR). Massachusetts-based Fernwood Ltd Llc has invested 0.2% in Digital Realty Trust, Inc. (NYSE:DLR). Los Angeles Cap & Equity Research invested 0.02% in Digital Realty Trust, Inc. (NYSE:DLR). Neuberger Berman Gru Ltd Liability Co accumulated 13,020 shares. Magnetar Financial Limited Com reported 0.03% in Digital Realty Trust, Inc. (NYSE:DLR). Forte Ltd Adv invested in 0.26% or 6,966 shares. Boston Llc holds 245,586 shares or 0.66% of its portfolio.

The stock decreased 2.00% or $2.16 during the last trading session, reaching $105.78. About 1.91 million shares traded or 54.44% up from the average. Digital Realty Trust, Inc. (NYSE:DLR) has risen 23.90% since January 16, 2017 and is uptrending. It has outperformed by 7.20% the S&P500.

Digital Realty Trust, Inc., a real estate investment trust , through its controlling interest in Digital Realty Trust, L.P., engages in the ownership, acquisition, development, redevelopment, and management of technology-related real estate. The company has market cap of $22.60 billion. It focuses on strategically located properties containing applications and activities critical to the day-to-day activities of technology industry tenants and corporate enterprise datacenter users, including the information technology departments of Fortune 1000 companies, and financial services companies. It has a 87.42 P/E ratio. The companyÂ’s property portfolio consists of Internet gateway properties, corporate datacenter properties, technology manufacturing properties, and regional or national offices of technology companies.

Since August 16, 2017, it had 0 insider purchases, and 1 sale for $3.00 million activity. Sharp Christopher had sold 25,733 shares worth $3.00 million.

Analysts await Digital Realty Trust, Inc. (NYSE:DLR) to report earnings on February, 15. They expect $1.52 EPS, up 6.29% or $0.09 from last year’s $1.43 per share. DLR’s profit will be $324.81 million for 17.40 P/E if the $1.52 EPS becomes a reality. After $1.51 actual EPS reported by Digital Realty Trust, Inc. for the previous quarter, Wall Street now forecasts 0.66% EPS growth.

Silence Therapeutics plc focuses on the discovery, development, and delivery of RNA therapeutics. The company has market cap of 133.33 million GBP. The firm creates short interfering RNA molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It currently has negative earnings. It is developing Atu027, a drug candidate that is in Phase IIa study for use in the treatment of pancreatic cancer, as well as various GalNAc-siRNA candidates for use in the treatment of iron overload disorders, acromegaly, cardiovascular disease, alcohol use disorder, and other metabolic diseases.

The stock decreased 1.04% or GBX 2 during the last trading session, reaching GBX 190.5. About 696 shares traded. Silence Therapeutics plc (LON:SLN) has 0.00% since January 16, 2017 and is . It has underperformed by 16.70% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com